Binding members for ige molecules
AssigneesAstraZeneca AB, MedImmune, LLC
InventorsDuncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
Life of this patent
Estimating the term…
Abstract
This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
Claims17
An isolated binding member specific for immunoglobulin E which binding member competes with Antibody 33 for binding to immunoglobulin E.
An isolated binding member specific for human immunoglobulin E comprising a set of CDRs:
- HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 wherein the set of CDRs has 8 or fewer amino acid substitutions from a reference set of CDRs in which:
- HCDR1 has the amino acid sequence of SEQ. ID. NO:
- 279;
- HCDR2 has the amino acid sequence of SEQ. ID. NO:
- 280;
- HCDR3 has the amino acid sequence of SEQ. ID. NO:
- 281;
- LCDR1 has the amino acid sequence of SEQ. ID. NO:
- 284;
- LCDR2 has the amino acid sequence of SEQ. ID. NO:
- 285;
- LCDR3 has the amino acid sequence of SEQ. ID. NO:
- 286;
An isolated binding member comprising a set of CDRs:
- HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 wherein HCDR3 comprises:
- the amino acid sequence of SEQ. ID. NO:
- 281;
An isolated binding member or VH domain comprising the antibody 1 HCDR3 (SEQ ID NO:
- 5) with one or more of the following substitutions (SEQ ID NO:
- 447):
- Kabat residue 95 replaced by H, L or S;
- Kabat residue 96 replaced by I, S, T, W, or F;
- Kabat residue 97 replaced by A, Y or F;
- Kabat residue 98 replaced by V, P or F;
- Kabat residue 99 replaced by A or Y;
- Kabat residue 100 replaced by G, I or S.
(canceled)
Dependencies are inferred from the claim text.